Yuka Takemon, Valerie Wright1, Bernard Davenport2, Daniel M Gatti1, Susan M Sheehan1, Kelsey Letson1, Holly S Savage1, Rachel Lennon2, Ron Korstanje3. 1. The Jackson Laboratory, Bar Harbor, Maine. 2. Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom. 3. The Jackson Laboratory, Bar Harbor, Maine Ron.Korstanje@jax.org.
Abstract
BACKGROUND: Mutations in COL4A5 are responsible for 80% of cases of X-linked Alport Syndrome (XLAS). Although genes that cause AS are well characterized, people with AS who have similar genetic mutations present with a wide variation in the extent of kidney impairment and age of onset, suggesting the activities of modifier genes. METHODS: We created a cohort of genetically diverse XLAS male and female mice using the Diversity Outbred mouse resource and measured albuminuria, GFR, and gene expression. Using a quantitative trait locus approach, we mapped modifier genes that can best explain the underlying phenotypic variation measured in our diverse population. RESULTS: Genetic analysis identified several loci associated with the variation in albuminuria and GFR, including a locus on the X chromosome associated with X inactivation and a locus on chromosome 2 containing Fmn1. Subsequent analysis of genetically reduced Fmn1 expression in Col4a5 knockout mice showed a decrease in albuminuria, podocyte effacement, and podocyte protrusions in the glomerular basement membrane, which support the candidacy of Fmn1 as a modifier gene for AS. CONCLUSION: With this novel approach, we emulated the variability in the severity of kidney phenotypes found in human patients with Alport Syndrome through albuminuria and GFR measurements. This approach can identify modifier genes in kidney disease that can be used as novel therapeutic targets.
BACKGROUND: Mutations in COL4A5 are responsible for 80% of cases of X-linked Alport Syndrome (XLAS). Although genes that cause AS are well characterized, people with AS who have similar genetic mutations present with a wide variation in the extent of kidney impairment and age of onset, suggesting the activities of modifier genes. METHODS: We created a cohort of genetically diverse XLAS male and female mice using the Diversity Outbred mouse resource and measured albuminuria, GFR, and gene expression. Using a quantitative trait locus approach, we mapped modifier genes that can best explain the underlying phenotypic variation measured in our diverse population. RESULTS: Genetic analysis identified several loci associated with the variation in albuminuria and GFR, including a locus on the X chromosome associated with X inactivation and a locus on chromosome 2 containing Fmn1. Subsequent analysis of genetically reduced Fmn1 expression in Col4a5 knockout mice showed a decrease in albuminuria, podocyte effacement, and podocyte protrusions in the glomerular basement membrane, which support the candidacy of Fmn1 as a modifier gene for AS. CONCLUSION: With this novel approach, we emulated the variability in the severity of kidney phenotypes found in human patients with Alport Syndrome through albuminuria and GFR measurements. This approach can identify modifier genes in kidney disease that can be used as novel therapeutic targets.
Authors: Grant Backer; Sean Eddy; Susan M Sheehan; Yuka Takemon; Anna Reznichenko; Holly S Savage; Matthias Kretzler; Ron Korstanje Journal: Physiol Genomics Date: 2018-04-13 Impact factor: 3.107
Authors: Lieselot L G Carrette; Chen-Yu Wang; Chunyao Wei; William Press; Weiyuan Ma; Raymond J Kelleher; Jeannie T Lee Journal: Proc Natl Acad Sci U S A Date: 2017-12-27 Impact factor: 11.205
Authors: Michael J Randles; Adrian S Woolf; Jennifer L Huang; Adam Byron; Jonathan D Humphries; Karen L Price; Maria Kolatsi-Joannou; Sophie Collinson; Thomas Denny; David Knight; Aleksandr Mironov; Toby Starborg; Ron Korstanje; Martin J Humphries; David A Long; Rachel Lennon Journal: J Am Soc Nephrol Date: 2015-04-20 Impact factor: 10.121
Authors: Mathieu Lemaire; Véronique Frémeaux-Bacchi; Franz Schaefer; Murim Choi; Wai Ho Tang; Moglie Le Quintrec; Fadi Fakhouri; Sophie Taque; François Nobili; Frank Martinez; Weizhen Ji; John D Overton; Shrikant M Mane; Gudrun Nürnberg; Janine Altmüller; Holger Thiele; Denis Morin; Georges Deschenes; Véronique Baudouin; Brigitte Llanas; Laure Collard; Mohammed A Majid; Eva Simkova; Peter Nürnberg; Nathalie Rioux-Leclerc; Gilbert W Moeckel; Marie Claire Gubler; John Hwa; Chantal Loirat; Richard P Lifton Journal: Nat Genet Date: 2013-03-31 Impact factor: 41.307
Authors: Daniel M Gatti; Karen L Svenson; Andrey Shabalin; Long-Yang Wu; William Valdar; Petr Simecek; Neal Goodwin; Riyan Cheng; Daniel Pomp; Abraham Palmer; Elissa J Chesler; Karl W Broman; Gary A Churchill Journal: G3 (Bethesda) Date: 2014-09-18 Impact factor: 3.154
Authors: Michael J Randles; Sophie Collinson; Tobias Starborg; Aleksandr Mironov; Mira Krendel; Eva Königshausen; Lorenz Sellin; Ian S D Roberts; Karl E Kadler; Jeffrey H Miner; Rachel Lennon Journal: Sci Rep Date: 2016-10-11 Impact factor: 4.379
Authors: Ron Korstanje; Christina R Caputo; Rosalinda A Doty; Susan A Cook; Roderick T Bronson; Muriel T Davisson; Jeffrey H Miner Journal: Kidney Int Date: 2014-02-12 Impact factor: 10.612
Authors: Raquel Martínez-Pulleiro; María García-Murias; Manuel Fidalgo-Díaz; Miguel Ángel García-González Journal: Int J Mol Sci Date: 2021-10-14 Impact factor: 5.923